FDA (CBER)
GUIDANCE DRAFT
Minimal Residual Disease and Complete Response in Multiple Myeloma: Use as Endpoints to Support Accelerated Approval; Draft Guidance for Industry
Published: 1/24/2026Detected: 3/19/2026
Summary preview
Minimal Residual Disease and Complete Response in Multiple Myeloma: Use as Endpoints to Support Accelerated Approval; Draft Guidance for Industry CDER/CBER/CDRH/OCE, January 2026.
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free account#Clinical Trials
#Accelerated Approval
#Multiple Myeloma
Official Source Document Source Verified
Access the original document directly from FDA CBER.
More from FDA (CBER)
- Recommendations for Reducing the Risk of Transfusion-Transmitted Hepatitis B Virus: Guidance for Industry11/3/2026
- Guidance for Industry: Potency Assurance for Cellular and Gene Therapy Products11/2/2026
- Individualized Human Genome Editing Products: Considerations for BLA Submission and Postapproval Management10/27/2026
- Compliance Policy Regarding Blood and Blood Component Donation Suitability, Donor Eligibility and Source Plasma Quarantine Hold Requirements: Guidance for Industry10/14/2026
- Blood Pressure and Pulse Donor Eligibility Requirements – Compliance Policy: Guidance for Industry10/14/2026